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pegfilgrastim and $30 for filgrastim. CONCLUSIONS: During 2007-2010, the major-
ity of patients did not pay OOP for G-CSF.
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ONCOLOGY DRUG USE AND OTHER HEALTH CARE RESOURCES WITHIN
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OBJECTIVES: In 2010 the UK government made an election pledge to improve ac-
cess to cancer drugs. The Interim Cancer Drugs Fund (ICDF) was introduced in
October 2010. This became the Cancer Drugs Fund (CDF) in April 2011. An addi-
tional £200 million per year, for three years was made available to fund cancer
drugs within England. The CDF money was allocated to the 10 Strategic Health
Authorities within England. The Cancer Network Pharmacists manage or are
closely involved with the CDFs. The objective of this research was to identify the
impact on oncology drug use and healthcare resources as a result of the introduc-
tion of the CDF. METHODS: A literature search was undertaken to identify any
research relevant to the CDF, cancer drug and healthcare resource use. A semi
structured questionnaire developed to capture quantitative and qualitative data
relating to changes in oncology drug use and healthcare resources. The question-
naire was piloted with three Cancer Network Pharmacists. Telephone interviews
were undertaken with Network Pharmacists covering the ten CDFs. The data col-
lected was assessed and evaluated, using a thematic framework. The results of the
researchwere then validated by three Cancer Network Pharmacists. RESULTS: The
CDF had led to a significant increase in use of some drugs, hospital attendances,
associated treatment costs and workload for Network Pharmacists. The commis-
sioning process for cancer drugs had changed; new drugs were not commissioned
unless recommended by NICE. CONCLUSIONS: The CDF had changed clinical prac-
tice for the management of certain cancers. The Increased use of cancer drugs had
led to additional costs which were not covered by the CDF. If the CDF disappeared
in 2014 it was unclear how some drugs would be funded which would have impli-
cations for clinical practice.
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DATA LINKAGE FOR HPV VACCINATION, SCREENING, AND CERVICAL CANCER
OUTCOMES: IS THERE AN EVIDENCE BASE FOR PUBLIC HEALTH DECISION-
MAKING ON CERVICAL CANCER PREVENTION STRATEGIES?
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OBJECTIVES: To assess the availability of linked data on HPV vaccination, screen-
ing, and cervical cancer outcomes to guide public health decision-making on cer-
vical cancer prevention strategies. METHODS: MEDLINE and Google Scholar (1/1/
2006-12/31/2011) were searched using keywords HPV registry, linkage, and cervical
cancer to identify countries with national HPV vaccination. Australia, New Zea-
land, Denmark, Norway, Greenland, Sweden, Iceland, the United Kingdom, Can-
ada, Mexico, and the United States were selected for detailed analysis based on
previous review frameworks (Wong et al. 2010; Sander et al. 2012). Information on
infrastructure, outcomes collected, surveillance registries and data linkage for
these countries through January 15, 2012was extracted from official health author-
ity websites and government reports. Documents not publicly available or without
data on these topics were excluded. RESULTS: Twenty peer-reviewed articles and
health authority documents were selected for review. Of the 11 countries evalu-
ated, 64% (7/11) have national HPV vaccination registries collecting vaccination
data and comprehensive cancer registries that include cervical cancer outcomes.
Four out of the eleven participate in theWHOHPV Laboratory Network that aims to
develop an international reference system for HPV assays to monitor performance
ofHPVvaccines. Five of the 11 countries have linkage of vaccination, cancer screen-
ing, and cancer registry records at the national level; however, the other six coun-
tries have potential linkages at provincial/territorial levels. None of the 11 coun-
tries had data on HPV DNA genotyping linked with other cervical cancer screening
and vaccination data. CONCLUSIONS: While fewer than half of the countries as-
sessed had nationally linked data on HPV vaccination, screening, and cervical can-
cer outcomes, the remaining countries have potential local-level linkages of these
data. Establishing data linkages across these sources of information can enable an
evidence base to explore the impact of national vaccination strategies and to in-
form cervical cancer prevention efforts.
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EFFECTS OF CLINICAL PHARMACIST INTERVENTIONS ON CLINICAL OUTCOMES
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OBJECTIVES: To assess the effect of clinical pharmacist interventions on the clin-
ical outcomes in oncology patients. METHODS: A total of 100 patients received
their chemotherapy cycles with clinical pharmacy interventions were enrolled in
the present study during January 2007 to January 2008. Clinical pharmacy interven-
tions include: Detecting medication errors by using a modified form of the Ameri-
can Society of Hospital Pharmacists (ASHP) worksheet. Correcting those errors and
sending recommendations to the medical staff. RESULTS: The clinical pharmacy
interventions reduced the number ofmedication errors from1548 to 444whichwas
statistically significant (p0.004). A total of 1104 clinical pharmacy interventions
were documented in this present study. Forty-five percent of clinical pharmacy
interventions have led to increase in the efficacy of chemotherapy regimen and
54.7% have led to decrease in the chemotherapy toxicity. Seventy six percent of the
errors recorded in the present study occurred in the prescribing stage, about 20% in
the administration stage and 3.8% in the dispensing stage. CONCLUSIONS: The
clinical pharmacy interventions among oncology patients can reduce the number
of medication errors; improve the clinical outcomes through increasing chemo-
therapy efficacy and reducing the toxicity.
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OBJECTIVES: The objective of this study is to determine how 25 major private US
payers use approved compendia and treatment guidelines when creating oncology
coverage policy for product usage outside of Food and Drug Administration (FDA)
approved indications.METHODS: Primary and secondary research was conducted
on the oncology coverage policies of US payers, n25, to determine if they follow
the Centers for Medicare & Medicaid Services (CMS) recommended guidelines on
use of compendia when making coverage policy decisions. Payer polices reviewed
include: United, Anthem, PacifiCare, Empire BC/BS, CIGNA, BC/BS of AB, Oxford,
BC/BS of TN, Kaiser, Humana, BC/BS of IL, CareSource, BC/BS of NC, CareFirst,
Wellpoint, BC/BS ofMN,Highmark, Aetna, GoldenRule, BC/BS ofMI, Independence,
BC/BS of FL, BC/BS of MA, BC/BS of WA, BC/BS of TX. RESULTS: Of the 25 US payers
surveyed, 12 payers follow CMS published guidelines that now mandate that cov-
erage can be given if an indication has a positive review in one of the approved
compendia and as long as no one compendia has a negative listing of the indica-
tion. A total of 8 payers have authored unique coverage policies that often are
broader than CMS’ guidelines. Such policies often include coverage for indications
listed in the National Comprehensive Cancer Center (NCCN) Drug & Biologics Com-
pendia as class IIb or III. The remaining five payers continue to rely on CMS’ previ-
ous policy prior to the expansion of the compendia list. CONCLUSIONS: The ma-
jority of the 25 US private payers surveyed have oncology coverage policies for non
FDA indicated uses that either mirror CMS’ compendia policy, or are somewhat
more liberal in their interpretation based on their review of published data and
reliance on lower levels of evidence.
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OBJECTIVES: To understand relative price differential for cancer drugs in the
United States and the United Kingdom. Develop implications for pricing strategy
and patient access for cancer drugs. METHODS: Ten branded cancer drugs were
selected and their prices for similar dose and packaging were compared in the
United States and the United Kingdom. Prices were analyzed for the end of 2010
and early 2011. Historical exchange rateswere used to convert British pounds to US
dollars. Relative price discount was calculated for all selected cancer drugs. KOLs
and payers were interviewed to understand current and future implications of this
price differential. RESULTS: The median price discount for selected ten branded
cancer drugs in theUnitedKingdomversus theUnitted Stateswas50%. The range
of discount for 10 branded cancer drugs was 27%-61%. The price discount for oral
small molecule drugs was higher than for biologics (55% vs. 45%). Since United
Kingdom is one of the few remaining free pricing markets in Europe, other Euro-
pean markets are likely to have even higher discounts relative to the prices in the
United States. Due to rising coinsurance of speciality products, US cancer patients
bear significantly higher cost than patients in the United Kingdom. KOL and payer
interviews suggest US pricing trends for cancer drugs are unlikely to be sustained
at this level in the future. CONCLUSIONS: US cancer drug prices are significantly
higher than the prices in the United Kingdom. This price differential is unlikely to
be sustained in the future.
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OBJECTIVES: To describe treatment patterns with surgery, radiation, and systemic
(drug) therapies in patients with metastatic melanoma in the United States.
METHODS: Using a large US medical claims database, patients were identified
between 2005 and 2010 using 2 melanoma diagnoses (ICD-9-CM: 172.xx, V10.82)
and2 diagnoses formetastasis (ICD-9-CM: 197.xx, 198.xx). The index datewas the
first date of metastasis diagnosis. Patients were followed from the index date to
death, disenrollment, or end of the study period (6/30/2010), whichever occurred
first. Surgery, radiation, and systemic therapies were examined descriptively. Fac-
tors influencing treatmentwere examined using a logistic regression separately for
surgery, radiation, and systemic therapy. RESULTS: A total of 2546 patients with
metastatic melanoma were included in the analyses. Mean ( standard deviation)
age was 60.6 ( 14.0) years old with 22.8% under 50 and 36.5%were female. Overall,
66.8% of patients had cancer treatment related surgery, 38.7% received systemic
therapies, 44.7% received radiation, and 17.7% of patients received all three treat-
ments. Logistic regressions revealed that patients with lung (p 0.0001), brain (p
0.0001), liver (p 0.0001), or bone (p 0.0001) metastases were less likely to have
surgeries; patients with lung (p  0.04), brain (p  0.001), or liver metastases (p 
0.03) were more likely to receive systemic therapies; as expected patients with
brain (p  0.0001) or bone metastases (p  0.0001) were more likely to have radia-
tion therapy. Patients being treated by oncologists were more likely to receive
systemic therapy (p 0.0001) or radiation (p 0.0001) while patients being treated
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